Xeljanz Lawsuits for Heart Attacks, Strokes, and Blood Clots, as well as Lymphoma, Lung Cancer, Other Cancers
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Our law firm is investigating Xeljanz lawsuits filed against Pfizer, the pharmaceutical company responsible for Xeljanz, for patients with cases of Xeljanz causing heart problems such as heart attacks, strokes, pulmonary embolism (PE), and deep vein thrombosis (DVT), as well as Xeljanz causing lymphoma, lung cancer, and other cancers.
UPDATE: On September 1, 2021, the FDA released this alerting new information based on its recent Xeljanz drug safety review:
The increased risk of blood clots and death has now been linked to the lower dose of Xeljanz — in addition to the higher dose of Xeljanz, as was reported previously
Put otherwise, both the Xeljanz 5 mg tablet and the Xeljanz 10 mg tablet are now known to be the cause of serious side effects and adverse drug reactions suffered by some patients who were using Xeljanz as prescribed by their doctor.
Similarly, the Xeljanz XR 11 mg tablet and Xeljanz XR 22 mg tablet have these same drug safety problems.
To learn more, we direct you to this September 2021 document, “FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions“, which provides detailed information about the most current Xeljanz drug safety findings by the FDA.
We expect this September 2021 FDA Xeljanz drug safety update will lead to the filing of more Xeljanz lawsuits against Pfizer.
According to the FDA, some of the serious side effects and adverse drug events and related to Xeljanz are:
- Heart Attacks
- Myocardial Infarction (MI)
- Strokes — Ischemic / due to a blood clot
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Arterial Thrombosis
- Lymphoma
- Lung Cancer
- Other Cancers
- Death
As stated above, our law firm is investigating possible Xeljanz lawsuits for patients who have suffered serious Xeljanz side effects or adverse drug reactions. We would like to help you or someone you know with a Xeljanz drug injury case. Please feel free to contact us, at your convenience.
Free Xeljanz Case Evaluation
We encourage you to submit a Xeljanz Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about your possible Xeljanz lawsuit. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Xeljanz
Xeljanz: Heart Attacks, Strokes, Cancers, Blood Clots, and Deaths – Updated FDA Warnings 2021
On September 1, 2021, we saw new FDA Xeljanz warnings about the increased risks of heart attacks, strokes, cancer, blood clots, and deaths. These Xeljanz drug safety problems have been associated with all doses of Xeljanz (5 mg tablet and 10 mg tablet) and Xeljanz XR (11 mg tablet and 22 mg tablet).
This September 2021 document, “FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions“, begins with the following new information:
To read more of this article, click below:
Based on a completed U.S. Food and Drug Administration (FDA) review of a large randomized safety clinical trial, we have concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with the arthritis and ulcerative colitis medicines Xeljanz and Xeljanz XR (tofacitinib). This trial compared Xeljanz with another type of medicine used to treat arthritis called tumor necrosis factor (TNF) blockers in patients with rheumatoid arthritis. The trial’s final results also showed an increased risk of blood clots and death with the lower dose of Xeljanz. A prior DSC based upon earlier results from this trial, reported an increased risk of blood clots and death only seen at the higher dose.
In more detail, from the Data Summary section of the above-referenced September 2021 document, here are the most recent FDA findings as regards various Xeljanz side effects:
There was an increased risk of death, MACE, malignancies, and thrombosis associated with both regimens of Xeljanz. The data showed evidence of a dose-dependent increased risk for [major adverse cardiovascular events (MACE) — defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke], all-cause mortality, and thrombosis at both doses of Xeljanz when compared to treatment with [tumor necrosis factor (TNF) blockers]. Additionally, the data showed evidence of a non-dose-dependent increased risk for malignancy excluding [nonmelanoma skin cancer (NMSC)] at both doses of Xeljanz when compared to TNF blockers. Lymphomas and lung cancers were observed at a higher rate in patients treated at both doses of Xeljanz compared to those treated with TNF blockers. In particular, a higher rate of lung cancers was observed in current or past smokers treated with Xeljanz. Current or past smokers had an additional increased risk of overall cancers.
We will continue to monitor the Xeljanz drug safety problems of serious side effects and adverse drug reactions suffered by some patients who were using Xeljanz as prescribed by their doctor.
Further, we expect these new FDA Xeljanz warnings in September will lead to the filing of more Xeljanz lawsuits against Pfizer for cases of Xeljanz causing heart problems such as heart attacks and strokes as well as Xeljanz causing cancers.
[Read article in full at original source]Earlier articles about Xeljanz by attorney Tom Lamb on the Side Effects Blog:
- FDA Advisory Committee Meeting Could Review Risk/Benefit Profiles for All JAK Inhibitors
- Possible FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq in Future
- Are Heart Problems and Cancers JAK Inhibitors Drug Class Safety Issues?
- New Xeljanz Warnings From FDA in 2021; Are Other JAK Inhibitors Next?
- Xeljanz 2021 FDA Warnings: Xeljanz Causing Heart Problems and Xeljanz Causing Cancer
- Xeljanz Side Effects Include Blood Clots, Pulmonary Embolism, And Serious Infections
- Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots
- Xeljanz FDA Drug Safety Communication About Increased Risks of Blood Clots And Death
- Serious Side Effects For Xeljanz 10 mg Dose Leads To European Drug Safety Regulatory Action
- Xeljanz Used For Ulcerative Colitis May Increase Risk Of Pulmonary Embolism
More articles about Xeljanz on our Drug Safety Developments website:
- Health Canada Issues Safety Review for Xeljanz in April 2021
- Xeljanz Safety Trial Results Which May Lead to Xeljanz Recall
- Will There Be a Xeljanz Recall in the Future?